Sotera Health reported higher revenue and earnings for the third quarter of 2026, with growth at both Sterigenics and Nelson Labs. The company also reaffirmed its full-year growth outlook, keeping its targets unchanged.
Key details
- Revenue rose 4.4% from the third quarter of 2025, both as reported and after adjusting for currency movements.
- Net income was $58 million, or 20 cents per diluted share.
- Adjusted EBITDA increased 3.9%, or 4.0% on a constant-currency basis. Sotera said its adjusted EBITDA margin expanded by nearly 100 basis points sequentially from the second quarter.
- Adjusted earnings per diluted share were 29 cents, up 12% year over year.
- Sterigenics revenue grew 8.2% and Nelson Labs revenue grew 9.2% on a constant-currency basis.
- Sotera maintained its 2026 outlook for constant-currency revenue growth of 5.25% to 6.75% and adjusted EBITDA growth of 5.75% to 7.25%.
What it means
The outlook reaffirmation leaves Sotera’s full-year targets unchanged. In the quarter, revenue growth was matched by gains in adjusted earnings, while the company reported sequential improvement in adjusted EBITDA margin.